ECSP19014247A - Formas de dosificación para tratar y prevenir trastornos del sueño - Google Patents

Formas de dosificación para tratar y prevenir trastornos del sueño

Info

Publication number
ECSP19014247A
ECSP19014247A ECSENADI201914247A ECDI201914247A ECSP19014247A EC SP19014247 A ECSP19014247 A EC SP19014247A EC SENADI201914247 A ECSENADI201914247 A EC SENADI201914247A EC DI201914247 A ECDI201914247 A EC DI201914247A EC SP19014247 A ECSP19014247 A EC SP19014247A
Authority
EC
Ecuador
Prior art keywords
dosage forms
treat
sleep disorders
prevent sleep
animal
Prior art date
Application number
ECSENADI201914247A
Other languages
English (en)
Inventor
Garth Whiteside
Donald J Kyle
Stephen C Harris
Ram P Kapil
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of ECSP19014247A publication Critical patent/ECSP19014247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La descripción se refiere a formas de dosificación para tratar o prevenir un trastorno del sueño por administración de un compuesto de la fórmula (1) (ver figura), o un compuesto de la fórmula (1A), (1B), (1C), (1D), (1E), o (1F) a un animal que necesita de tal tratamiento. En determinadas modalidades, tales compuestos tratan o previenen de modo eficaz un trastorno del sueño en el animal, mientras se producen menos cantidad de efectos colaterales en comparación con compuestos previamente disponibles.
ECSENADI201914247A 2016-07-26 2019-02-26 Formas de dosificación para tratar y prevenir trastornos del sueño ECSP19014247A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662366960P 2016-07-26 2016-07-26
US201762536097P 2017-07-24 2017-07-24
PCT/IB2017/054506 WO2018020418A1 (en) 2016-07-26 2017-07-25 Treatment and prevention of sleep disorders

Publications (1)

Publication Number Publication Date
ECSP19014247A true ECSP19014247A (es) 2019-05-31

Family

ID=59714072

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201914247A ECSP19014247A (es) 2016-07-26 2019-02-26 Formas de dosificación para tratar y prevenir trastornos del sueño

Country Status (20)

Country Link
US (4) US10974081B2 (es)
EP (1) EP3490563A1 (es)
JP (2) JP7198197B2 (es)
KR (2) KR102531366B1 (es)
CN (1) CN109689058B (es)
AU (2) AU2017304898B2 (es)
BR (1) BR112019001457A2 (es)
CA (1) CA3031388C (es)
CL (1) CL2019000190A1 (es)
EC (1) ECSP19014247A (es)
IL (1) IL264294B (es)
JO (1) JOP20190008A1 (es)
MX (1) MX388469B (es)
NZ (1) NZ750817A (es)
PH (1) PH12019500177A1 (es)
SG (1) SG11201900486WA (es)
TN (1) TN2019000019A1 (es)
TW (1) TWI661827B (es)
WO (1) WO2018020418A1 (es)
ZA (1) ZA201901055B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
MX2020007817A (es) 2018-01-24 2020-09-25 Purdue Pharma Lp Prevención y tratamiento del trastorno del sueño.
WO2019200474A1 (en) * 2018-04-16 2019-10-24 Technologies Hop-Child, Inc. Systems and methods for the determination of arousal states, calibrated communication signals and monitoring arousal states
KR102198846B1 (ko) * 2018-06-29 2021-01-05 다인기술 주식회사 배뇨에 관한 설문을 수행하는 방법, 시스템 및 비일시성의 컴퓨터 판독 가능 기록 매체
US11547350B2 (en) 2018-12-26 2023-01-10 Industrial Technology Research Institute Personalized parameter learning method, sleep-aid device and non-transitory computer readable medium
CN111359074B (zh) * 2018-12-26 2022-08-02 财团法人工业技术研究院 个人化参数学习方法、睡眠辅助装置及存储介质
EP3917621A1 (en) * 2019-01-31 2021-12-08 Purdue Pharma LP Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
JP2022547604A (ja) * 2019-09-13 2022-11-14 武田薬品工業株式会社 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
EP4340837A4 (en) 2021-05-21 2025-04-09 Purdue Pharma L.P. METHODS FOR THE TREATMENT OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME
TWI804037B (zh) * 2021-11-02 2023-06-01 長庚醫療財團法人高雄長庚紀念醫院 生酮飲食之評估系統及其運作方法
CN119421705A (zh) * 2022-06-24 2025-02-11 普渡制药公司 治疗或预防膀胱过度活动综合征的方法
IL326884A (en) 2023-10-19 2026-04-01 Purdue Pharma Lp Sunobinop for use in method of treating alcohol use disorder
WO2026064338A1 (en) * 2024-09-18 2026-03-26 Sirtsei Pharmaceuticals, Inc. Compositions and methods for treating diseases or conditions associated with sleep

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
ATE301457T1 (de) 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US6572891B1 (en) 1999-10-23 2003-06-03 Alkaloid Ad Sublingual oral dosage form
US7566728B2 (en) 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
JP4739217B2 (ja) 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
SA04250305B1 (ar) 2003-09-25 2008-06-02 سولفاي فارماسوتيكالز بي . في مشتقات بنزيميدازولون cenzimidazolone وكينازولينون quinazolinone كمساعادات على مستقبلات ORL1 البشرية
US7355045B2 (en) 2004-01-05 2008-04-08 Applera Corporation Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof
WO2006025267A1 (ja) * 2004-08-31 2006-03-09 Mitsubishi Pharma Corporation Per2タンパク質レベルの低下を作用機序とする睡眠障害治療薬
CA2664315C (en) 2006-09-15 2016-01-19 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
WO2009027820A2 (en) * 2007-08-31 2009-03-05 Purdue Pharma L.P. Substituted-quinoxaline-type-piperidine compounds and the uses thereof
EP2254556A2 (en) 2008-03-11 2010-12-01 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
RS52590B2 (sr) * 2008-07-21 2018-05-31 Purdue Pharma Lp Jedinjenja tipa supstituisanog hinoksalina sa premošćenim piperidinom i njihova upotreba
ES2583146T3 (es) 2011-12-01 2016-09-19 Purdue Pharma L.P. Compuestos de piperidina de tipo quinoxalina sustituidos con azetidina y usos de éstos
US10118927B2 (en) * 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
US9040533B2 (en) * 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
JOP20190008A1 (ar) * 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم

Also Published As

Publication number Publication date
KR102531366B1 (ko) 2023-05-12
CN109689058B (zh) 2022-03-22
JP2019523269A (ja) 2019-08-22
EP3490563A1 (en) 2019-06-05
CL2019000190A1 (es) 2019-06-07
ZA201901055B (en) 2019-12-18
JP7291172B2 (ja) 2023-06-14
BR112019001457A2 (pt) 2019-05-07
JP7198197B2 (ja) 2022-12-28
AU2020273332B2 (en) 2022-11-24
IL264294B (en) 2022-06-01
CA3031388C (en) 2023-02-14
CN109689058A (zh) 2019-04-26
US20240058333A1 (en) 2024-02-22
US11738023B2 (en) 2023-08-29
NZ750817A (en) 2020-07-31
TW201817423A (zh) 2018-05-16
KR20210013319A (ko) 2021-02-03
AU2020273332A1 (en) 2020-12-17
US12370191B2 (en) 2025-07-29
US20190282836A1 (en) 2019-09-19
US20210330994A1 (en) 2021-10-28
PH12019500177A1 (en) 2019-10-14
MX2019001036A (es) 2019-06-10
JOP20190008A1 (ar) 2019-01-24
KR20190029682A (ko) 2019-03-20
JP2021120379A (ja) 2021-08-19
US10974081B2 (en) 2021-04-13
AU2017304898A1 (en) 2019-03-07
CA3031388A1 (en) 2018-02-01
WO2018020418A1 (en) 2018-02-01
US20260007660A1 (en) 2026-01-08
MX388469B (es) 2025-03-20
IL264294A (en) 2019-02-28
KR102210209B1 (ko) 2021-02-01
AU2017304898B2 (en) 2020-08-20
SG11201900486WA (en) 2019-02-27
TWI661827B (zh) 2019-06-11
TN2019000019A1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
MX2019001036A (es) Tratamiento y prevencion de los trastornos del sueño.
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
MX376193B (es) Compuestos para tratar el cancer cerebral.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX384403B (es) Terapia de combinación para el tratamiento del cáncer.
PH12017500933A1 (en) Sublingual administration of riluzole
CL2017002242A1 (es) Método para tratar un tumor cerebral
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
MX2018010852A (es) Metodos para tratar la depresion con antagonistas del receptor de orexina-2.
PH12017500934A1 (en) Sublingual formulation of riluzole
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
PE20181351A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y articulos de la misma
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
AU2017268006A8 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX2015013186A (es) Adminitracion craneal de productos farmaceuticos.
BR112017027277A2 (pt) ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
CL2021000743A1 (es) Métodos para tratar trastornos mieloproliferativos
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
MX2019006143A (es) Metodos de administracion de tratamiento antifibrotico.
AR097590A1 (es) Métodos para tratar el síndrome del x frágil y trastornos relacionados
ES2721922T3 (es) Tratamiento o prevención del daño neuronal no inflamatorio por traumatismo cerebral e ictus utilizando mentol, linalool y/o icilina